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a  b  s  t  r  a  c  t
Organophosphates  (OPs)  are  cholinesterase  inhibitors  that lead  to a characteristic  toxidrome  of  hyper-
secretion,  miosis,  dyspnea,  respiratory  insufﬁciency,  convulsions  and,  without  proper  and  early  antidotal
treatment,  death.  Most  of  these  compounds  are  highly  lipophilic.  Sulfur  mustard  is  a toxic  lipophilic  alky-
lating  agent,  exerting  its damage  through  alkylation  of  cellular  macromolecules  (e.g.,  DNA,  proteins)  and
intense activation  of  pro-inﬂammatory  pathways.  Currently  approved  antidotes  against  OPs  include the
peripheral  anticholinergic  drug  atropine  and  an  oxime  that  reactivates  the  inhibited  cholinesterase.  Ben-
zodiazepines  are  used  to  stop  organophosphate-induced  seizures.  Despite  these  approved  drugs,  efforts
have  been  made  to introduce  other  medical  countermeasures  in  order  to attenuate  both  the  short-termrganophosphates
ulfur mustard
ntidotes
oisoning
hemical Warfare agents
and  long-term  clinical  effects  following  exposure.  Currently,  there  is no  antidote  against  sulfur  mustard
poisoning.  Intravenous  lipid  emulsions  are  used  as a source  of  calories  in parenteral  nutrition.  In  recent
years,  efﬁcacy  of  lipid  emulsions  has  been  shown  in the treatment  of poisoning  by fat-soluble  compounds
in  animal  models  as well  as clinically  in  humans.  In this  review  we  discuss  the  usefulness  of intravenous
lipid  emulsions  as  an  adjunct  to the  in-hospital  treatment  of chemical  warfare  agent  poisoning.
©  2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the  CC  BY
license  (http://creativecommons.org/licenses/by/4.0/).
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. Introduction
Organophosphates (OPs) are cholinesterase inhibitors, that are
idely used as pesticides, but still represent a major health problem
n the world over [37,38]. A group of OP compounds developed as
hemical nerve agents have been used in a variety of international
onﬂicts and terror events [43,122]. Despite international efforts to
utlaw their use for this purpose, they are still being used against
nemy forces and innocent civilians [104]. Recently we have wit-
essed the devastating consequences of using the nerve agent sarin
n the Syrian conﬂict [43,116,133].
OP poisoning leads to a characteristic toxidrome that includes
uscarinic, nicotinic and central nervous system signs and
ymptoms [104,116,122]. Without proper antidotal treatment
dministered immediately after exposure, and depending on the
ose, victims may  suffer from convulsions, respiratory failure and
ltimately, death. Currently accepted antidotal treatment includes
he anticholinergic drug atropine, and a reactivator from the oxime
amily. Benzodiazepines are added to terminate seizures [43,122].
owever, it is evident that even when given early after poisoning,
he response to these antidotes is not optimal and does not pre-
ent long-term emotional, neurological and cognitive deﬁciencies
ccurring in subjects surviving the acute poisoning. Considerable
ffort has focused on ﬁnding more efﬁcient medical countermea-
ures [42,113,150,151].
Most of the OPs are lipophilic compounds, and as such, may
emain in body tissues, especially fat, for long periods of time,
andating a prolonged medical observation time following initial
ntidotal treatment [38,39,94,108].
Sulfur mustard is a toxic lipophilic alkylating agent widely used
n the past as a chemical warfare agent (CWA) [68,75], and recently
eported to be used by the Islamic State Jihadist group ISIS [128].
t exerts its damage through alkylation of cellular macromolecules
e.g., DNA and intra- and extra-cellular proteins) and intense acti-
ation of pro-inﬂammatory pathways [68]. Following exposure, an
n-going worsening process of vesication appears, depending on
he extent of exposure and whether the victim was  decontaminated
n a timely manner [68]. The systems most affected are the lungs
nd airways, skin, and mucous membranes including the eyes. It
akes several hours for many of the signs and symptoms to appear
53,68]. Once absorbed into the tissues, there are no currently avail-
ble medical countermeasures to prevent the injury—apart from
iminishing the extent of the injury with corticosteroids and non-
teroidal anti-inﬂammatory drugs (NSAIDs), and certain treatment
djuncts aimed at reducing the time-to-healing of local injuries
32,53].
Intravenous lipid emulsions (ILE) were introduced in the early
960’s as an energy substrate and calorie source containing essen-
ial fatty acids, given parenterally as a nutritional supplement
n patients with major injury, infection or nutritional deple-
ion [14,99]. It is widely used in neonatal intensive care, where
nfants are frequently dependent on intravenous nutrition in the
arly weeks of life [137]. For more than a decade, ILE were
hown to be effective in the treatment of poisonings by fat-
oluble compounds, especially local anesthetics. ILE has been
hown to rapidly reverse the clinical toxicity induced by a vari-
ty of compounds with diverse kinetics and mechanisms of action
17,20,21,23,117,142,143,145,149].
Recently, Zhou et al. [154] proposed to use a combina-
ion of ILE and charcoal hemoperfusion in patients with severe
P poisoning. They suggest that with this strategy, care-
ivers can remove the OP, decrease the amount of antidotes
eeded, reduce possible side-effects of the drugs, and mean-
hile provide an additional energy substrate for the victims.
e  have found no evidence in the literature on the use of ILE in
he treatment of sulfur mustard injury.Reports 3 (2016) 202–210 203
In this review we will discuss the potential role of ILE as an
adjunct to the in-hospital treatment of CWA  poisoning.
2. Proposed mechanisms of action
The exact mechanisms by which ILE exert their beneﬁcial effects
are not fully understood, and several have suggested synergis-
tic effects of several mechanisms [47,48,61]. The mechanisms of
action can be divided into intravascular, membrane, and intracel-
lular effects [149]. The original theory explaining the mechanism
of lipid rescue was  that of “lipid sink”, suggesting sequestration
of lipophilic compounds to an expanded intravascular lipid phase,
extracting the offending agent from the target tissue, and revers-
ing the toxicity [61,117,118,143,149]. In support of this theory,
toxic drug levels were shown to decrease more rapidly in tissues
following the administration of ILE [35,63,98,144,148,149], and
intravenous lipid emulsions were shown to bind lipid-soluble drugs
in vitro [51,89]. Other hypotheses relate to the mechanism by which
ILEs facilitate cardiac rescue from drug poisoning. These include (1)
increasing myocardial energy substrate delivery and a direct car-
diotonic effect of ILE on the poisoned heart, thus improving cardiac
function (a so-called metabolic effect) [7,57,117,126,130,143,149],
and (2) an effect of ILE on calcium ion channels through high
levels of long-chain fatty acids, leading to increased cardiomy-
ocyte calcium and positive inotropic effect which improves the
heart contractility [54,66,105]. The latter theory seemed unlikely
in view of evidence of the inhibitory effects of fatty acids on Ca2+
ion intake by neurons [48]. Recently, the cardioprotective action
of the long-chain fatty acids in Intralipd® was found to involve
Ca2+-homeostasis and rescue signaling pathways that regulate the
opening of the mitochondrial permeability transition pore (mPTP)
[103,112]. This activity requires fatty acid metabolism and involves
production of reactive oxygen species (ROS) by the mitochondria
which, in turn, activates rescue pathways [81,134]. The relative
contribution of the “lipid sink” and other mechanisms to the ben-
eﬁcial effect of ILE on systemic bupivacaine toxicity has been
studied using physiologically-based pharmacokinetic and pharma-
codynamic (PBPK/PD) modeling [131]. Pharmacokinetic analysis
has shown that the amount of bupivacaine sequestered from the
heart and brain tissues by standard ILE infusion is too low to account
for reversal of toxicity, suggesting that additional mechanisms
must be involved [76]. A later study, combining dose-response
of the effect of ILE in bupivacaine-poisoned rats with PBPK/PD
modeling, has shown that ILE exerts its beneﬁcial effect by three
mechanisms operating in concert: lipid scavenging of the drug, a
volume effect, and the cardiotonic effect, which was  found to be
essential for reversal of toxicity [46]. Support for the theory sug-
gesting combined action of these mechanisms is found in the recent
detailed mechanistic study by Fettiplace et al. [47]. This study sug-
gested that the “lipid sink” concept is inaccurate, and replaced it
with the more accurate “lipid shuttle” mechanism [48]. Additional
mechanisms besides lipid sequestration extend the range of action
of ILE to less lipophilic compounds.
3. The use of ILE in over-dose and poisonings
In recent years, several review articles summarized
current experience in animal models and in humans
[17,20,23,70,100,117,149], showing repeatable positive effects,
suggesting a role for ILE as an antidote for poisoning by lipophilic
compounds. Efforts have been initiated to collect all data in a
global registry (e.g., http://www.lipidrescue.org and http://www.
lipidregistry.org) [23,117,149]. In the recent LIPAEMIC report, Cave
et. al. [24] summarized the results from three years of operation
(2009–2012) of the lipid rescue registry. The ﬁrst successful use
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f ILE in a clinical setting of rescue was in 2006 in a patient with
upivacaine-induced cardiovascular collapse [115]. Since then,
he list of lipophilic drugs and compounds for which ILE therapy
eems to be helpful has expanded [8,17,117,145,149,155], to
nclude a number of beta-blockers [19,21,33,58,127], calcium
hannel blockers [7,26,130], a variety of psychotropic drugs
6,49,52,57,124,147], muscle relaxants and macrocytic lactones
72].
Han et al. [56] described a case poisoning in a 52 years old
an  by glyphosate-surfactant (GlySH), a herbicide consisting of
he water-soluble glyphosate and an amphiphilic surfactant [25].
e was admitted with impaired consciousness, hypotension and
radycardia. He was mechanically ventilated, treated with vaso-
ressors and ﬂuids, and had a gastric lavage. However, two and
 half hours after initiation of treatment, he remained in a criti-
al condition. At this point the caregivers decided to use 20% ILE.
hortly after his condition stabilized, he was extubated, and several
ays later was discharged with no sequelae. Mahendrakar et al.
84] reported another case of GlySH ingestion in a 35 years old
an. He developed cardiovascular shock and renal failure. He too
as treated with ﬂuids, vasopressors, veno-venous hemodiaﬁltra-
ion and 20% ILE. Though this combined treatment was given for a
eriod of several days before clinical improvement was  achieved,
he patient survived and was discharged home with no reported
equelae. Circulatory shock is a major cause of death in GlySH poi-
oning, usually refractory to ﬂuid resuscitation and vasopressors
114]. There is no speciﬁc antidote to GlySH. It is a water-soluble
ompound, in which the added surfactant is capable of solubilizing
ipids [153]. Thus, ILE may  probably reduce the effect of GlySH poi-
oning by lowering free surfactant concentration, thus preventing
ts cardiovascular toxicity [56].
Several organizations have included ILE therapy in their guide-
ines for the treatment of systemic toxicity from local anesthetics,
hough it is still deﬁned as a Class IIa treatment modality—meaning
hat there is conﬂicting evidence and/or divergence of opinion
bout its efﬁcacy, but the weight of evidence is in favor of usefulness
or this purpose [4,97,109]. In fact, the American Society of Regional
nesthetics (ASRA) has recommended ILE as a ﬁrst-line treatment
n local anesthetic systemic toxicities and not just as rescue therapy
97]. The American Heart Association (AHA), in its 2015 guidelines
elated to cardiovascular resuscitation and emergency cardiovas-
ular care, adopted a more conservative approach. They endorsed
LE therapy only for bupivacaine overdose and for rescue therapy
n other circumstances of cardiopulmonary arrest [77].
. Safety of ILE
Reports of complications, especially in neonates, following the
dministration of large volumes of highly concentrated ILE include
epsis, lipid deposition in the pulmonary vasculature, increased
ulmonary artery pressure, the development of chronic lung dis-
ase, and a reduction in arterial oxygen concentration during
nfusion [69,91,125,137–139]. Importantly, such events have not
een reported in the early literature that described the use of ILE as
n antidote in drug-induced poisonings [149]. A recent review cited
8 case reports (in 12 articles of the 94 included in the analysis) of
dverse effects of ILE when given in exceptionally high doses as
n antidote in poisoning [17]. These effects included extreme tran-
ient lipemia, pancreatitis, ARDS, and two cases of post-ILE cardiac
rrest [16,17,27,79,152]. The causal relation to ILE infusion is not
lear. However, it is advisable to monitor patients several hours
fter lipid-based resuscitation [17,27].
Studies on the untoward effects of ILE when used for par-
nteral nutrition in patients with acute respiratory distress
yndrome (ARDS) raised concerns of possible exacerbation of theirReports 3 (2016) 202–210
condition [20]. Some studies demonstrated transient reduction
in blood oxygenation and worsening of hemodynamic param-
eters during infusion of lipid emulsions containing long-chain
or long chain/medium chain fatty acids in these patients (with
ARDS) [69,78,86,139]. However, others showed either no-effect or
some improvement [44,85,119]. Of particular interest, the study
of Hwang et al. [69] showed that ILE infusion did not affect oxy-
genation and pulmonary hemodynamics in patients with normal
lung function and respiratory conditions like pulmonary infection
and COPD. Also, these results were found to vary with the fatty
acid composition of the ILE and speed of infusion. These variable
responses were attributed to variable production of vasodilatory
or vasoconstrictory prostaglandins [86,120,129]. Moreover, other
reports of successful use of parenteral ILE in cases of overdose of
verapamil [80,123] buproprion, and amitriptyline [79,124], showed
that ARDS, when developed, was  managed promptly and success-
fully without any recognized effect on the patient outcome.
ILE is not recommended as a rescue treatment during hypoxia
[59,64,88,146]. These observations come in accordance with results
showing ILE in ischemia may  worsen myocardial oxidative damage
[7].
Besides issues of direct safety, there is some evidence of inter-
action between ILE and lipophilic drugs used for resuscitation,
potentially narrowing their efﬁcacy [18,98]. It has been shown that
high doses of epinephrine may  impair the efﬁcacy of ILE [64], while
low doses of epinephrine may  improve it [65]. Another caveat is
the use of ILE early after ingestion of toxicants [22]. It has been
shown that blood lipids may  enhance gastrointestinal absorption
of toxicants, thereby increasing their likelihood of systemic tox-
icity [36,60,83,107]. It should be mentioned that the reports of
successful use of ILE for resuscitation in cases of drug ingestion were
primarily in severely symptomatic patients, likely to have already
experienced signiﬁcant distribution of the toxicant. In summary,
although the safety issues and caveats discussed above are signiﬁ-
cant, ILE infusion should be entertained as a life-saving regimen in
circumstances of otherwise fatal drug/chemical overdose.
5. ILE and OP poisoning
The fast progression-to-death of the organophosphate tox-
idrome warrants the use of antidotes as early as possible [116].
The antidotes include atropine as a muscarinic receptor antago-
nist, oximes as AChE reactivators, and benzodiazepines to stop
seizures [43,116,122]. However, even after using currently avail-
able treatments (e.g., atropine, oximes, and benzodiazepines),
victims often develop long-term sequelae, mainly learning and
memory deﬁcits, intermediate syndrome and OP-induced delayed
neuropathy (OPIDN) [2,34]. The availability of OPs and their
devastating effects are the reason for on-going efforts in devel-
oping effective medical countermeasures. Many of the OPs are
lipophilic compounds. It therefore appeared reasonable to deter-
mine whether ILE would be useful in OP poisoning [40,141,154].
So far, there have been several animal studies on the use of ILE
in experimental OP poisoning, though with inconsistent results.
Recently, Mir  and Rasool [90] reported on successful reversal
of severe OP-induced cardiotoxicity in human OP  poisoning by
Intralipid, which seems to be the ﬁrst report of ILE therapy in human
OP poisoning.
5.1. Lipophilicity of CWA  and organophosphate pesticidesAs ILE therapy was mainly based on scavenging of lipophilic
compounds, studies aimed at predicting its efﬁcacy corre-
lated the lipophilicity of different agents, measured by the
octanol–water partition coefﬁcients (log Kow), with pharmacolog-
A. Eisenkraft, A. Falk / Toxicology 
Table  1
Partition coefﬁcients (log Kow) of chemical warfare agents and selected toxicants
[11,51,82,93]. CWA, chemical warfare agents; OP, organophosphates.
Compound Type Log Kow
Amitriptyline Tricyclic antidepressant 5.0
Parathion OP pesticide 3.83
Diazinon OP pesticide 3.81
Bupivacaine Local anesthetic 3.4
Sulfur mustard CWA, blister 2.41
Malathion OP pesticide 2.4
VX  CWA, nerve 2.09
Diazo– OP pesticide, active metabolite of diazinon 2.07
Paraoxon OP pesticide, active metabolite of parathion 1.98
Mepivacaine Local anesthetic 1.9
Soman (GD) CWA, nerve 1.78
Sarin (GB) CWA, nerve 0.3
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Glyphosate OP herbicide −4.0
cally relevant properties like scavenging from blood [17,51,89].
he octanol–water partition coefﬁcients of the prominent chemi-
al warfare agents sulfur mustard (HD), VX, sarin (GB), and soman
GD) are listed in Table 1, together with some OP pesticides and
rugs whose poisoning was treated successfully with ILE infusion
or reference. The OP pesticides parathion and diazinon, as repre-
entatives of a group of highly-lipophilic toxicants, are somewhat
ore lipophilic than the “gold standard” bupivacaine. Their active
etabolites diazo–oxon and paraoxon are less lipophilic and, if we
dopt log Kow > 2 as a criterion for high lipophilicity [17], they can be
iewed as marginally lipophilic. The chemical warfare agents sulfur
ustard and VX are of low lipophilicity (Kow = 2.4 and 2.1, respec-
ively). The lipophilicity of the G-type agent soman is marginal,
hile sarin is non-lipophilic. The relative low lipophilicity of the
rominent chemical warfare agents does not preclude consider-
ng a role for ILE infusion in the emergency medical management,
s successful application of ILE infusion was observed with non-
ipophilic compounds like atenolol [20,21], for which mechanisms
ther than lipid scavenging may  be attributable.
.2. In vitro studies
In an in vitro investigation, Von Der Wellen et al. [141] stud-
ed the interactions of clinically approved Intralipid emulsions
ith OP nerve agents (GA, GB, GD, GF, and VX) and pesticides
paraoxon–ethyl and malaoxon), using an AChE inhibition assay
nd looking at the OP degradation kinetics. The aim was to validate
he physical rationale for in-vivo studies of ILE in OP poisoning.
hey found that the incubation of OP compounds in intravenous
ipid emulsions resulted in stabilization of the OPs, and only a neg-
igible effect on degradation was recorded [141]. Though in this
n vitro study an interaction of the OPs with the lipid phase was
een, it showed no evidence for a beneﬁcial effect via modulation
f OP degradation.
.3. Animal studies
Bania et al. [5] tested whether pretreatment with Intralipid
ould protect mice from lethal exposure to paraoxon (adminis-
ered 20 min  following ILE). The results showed small, statistically
nsigniﬁcant increase in the LD50, time-to-onset of symptoms,
nd time-to-death in ILE-treated animals compared to saline con-
rols, and were, hence, inconclusive. In the study of Moshiri et al.
93], rats were treated with ILE after oral exposure to diazi-
on and followed for 48 h. Again, the use of ILE failed to reduce
ortality or increase survival time when compared with normal
aline. Dunn et al. [36] also showed that ILE infusions starting ﬁve
inutes after oral exposure to parathion had no positive clinicalReports 3 (2016) 202–210 205
effect. However, when started 20 min  after exposure, it prolonged
the time-to-apnea, although no difference was shown in the num-
bers of animals with respiratory arrest. Because of the complex
toxicokinetics of parathion, the reported effects of lipid infusion in
the latter study are difﬁcult to explain. However, it is possible that
lipid scavenging may  be involved [36], and this study emphasizes
the importance of lipid infusion timing relative to the peak blood
concentration of the toxicant [36]. The timing of ILE administration,
which is likely to signiﬁcantly affect its efﬁcacy in oral intoxication,
was apparently overlooked in acute studies of Moshiri et al. [93],
but was fundamental in the experimental design of Dunn et al. [36],
who selected the ILE starting times to represent the time points of
initial and peak blood parathion concentrations after oral dosing.
On an ironic note, the delay in onset of some critical toxic effects
may allow the caregiver enough time to use currently available
antidotes and supportive care.
In these above animal studies ILE was  given alone, and not in
conjunction with currently approved OP antidotes. Since OPs exert
their effect relatively fast, it is advisable to perform studies to test
the synergistic effect of ILE with the known antidotes, before rul-
ing out its use. Such a study was performed by Kayipmaz et al. [73],
in which rats were exposed to the lipophilic OP methyl parathion
through intragastric gavage, and treated with the accepted com-
bination of antidotes, including repeated doses of atropine for a
total of 12 h, an oxime reactivator (pralidoxime). One of the groups
was also treated with ILE (detailed protocol1 in Kayipmaz et al.
[73]). Animals treated with ILE were found to have reduced brain,
liver, and pancreatic injury when compared with animals treated
with the accepted antidotes alone. More speciﬁcally, the authors
described reduced expansion of glial cell feet following treatment
with ILE, suggesting protection of the blood–brain barrier. Since the
animals were exposed to a sub-lethal dose of methyl parathion,
animals did not suffer from respiratory failure, convulsions, car-
diac arrest or loss of consciousness. However, the authors indicated
that the animals were extremely agitated upon receiving the ILE
treatment.
5.4. Human case report—reversal of cardiovascular failure in
suicidal parathion poisoning by i.v. administration of intralipid
Recently, Mir  and Rasool [90] reported the case of a severely
OP-poisoned patient that, on admission, presented with seizures,
bradycardia, restlessness, miosis, hypersecretion, hypotension and
respiratory insufﬁciency. She was  decontaminated, intubated and
ventilated, received ﬂuid resuscitation, and was treated with
repeated doses of atropine and pralidoxime according to the World
Health Organization (WHO) protocol. The seizures were treated
with phenytoin. Laboratory tests revealed severe acidosis, hypoxia,
hypercapnia and a low level of plasma ChE. Chest X-ray was
suggestive of ARDS. The patient had poor response to both anti-
dotes and to supportive treatment, necessitating the initiation of
vasopressor support. Despite the use of vasopressors, bradycardia
with hypotension continued, followed by the onset of arrhythmias
with fast ventricular rate, QT prolongation progressing to ventric-
ular tachycardia (VT) and ventricular ﬁbrillation within several
hours of exposure. Standard cardiopulmonary resuscitation efforts
including repeated cardioversion and the use of amiodarone and
high-dose inotrope drugs failed to re-establish an effective car-
diac rhythm. As repeated attempts of standard cardiopulmonary
resuscitation failed, boluses of 20% intralipid were given i.v. up to
a total of 300 mL,  with the concomitant disappearance of extrasys-
toles, decreased QRS duration, and restoration of sinus rhythm.
The need for vasopressor support and atropine started gradually to
decrease, parallel with improvement in level of consciousness and
resolution of respiratory distress. As expected, plasma ChE began
to rise after the 3rd day and returned to normal values on the 7th
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ay. On the 5th day of admission the patient was extubated, and
y the 7th day atropine was discontinued. The authors attributed
he successful reversal of the cardiotoxicity to sequestration of
he highly-lipohilic parathion in a lipid scavenging mechanism,
lthough direct cardiotonic and cardioprotective mechanisms, that
ere found to be as important in other instances of drug-induced
ardiotoxicity [46–48,76,103,131], cannot be ruled out, especially
f the active agent may  be the more potent and less lipophilic
etabolite paraoxon.
.5. Other routes for lipid emulsion treatment in OP poisoning
.5.1. Oral administration
Tuzcu et al. [132] treated malathion-exposed rats (p.o.) with
n oral lipid emulsion (ILE given p.o.), and in this preliminary
tudy showed that the oral emulsion prevented OP-induced pan-
reatic injury, speciﬁcally -cell injury, if given up to six hours
ost-exposure. When giving the emulsion 12 h post exposure no
ffect was noted. Another group also looked at the effect of oral
ipid emulsion in rats following oral exposure to malathion or
hlorpyriphos, both lipophilic compounds, in different time points
12,101]. Since it was shown in the past that OP exposure leads
o oxidative stress [1,71,92,106,111,140], this group decided to
ocus on total antioxidant capacity (TAC) and total oxidant sta-
us (TOS) of the rat brain, as well as on immunohistochemical
taining of caspase-3 as a marker for apoptosis. In the malathion
tudy, lipid emulsion was given either immediately or with a delay
f six and 12 h post-exposure [12]. In the malathion-poisoned
nimals, TOS levels were signiﬁcantly increased and TAC levels
educed compared to controls and immediate lipid-treated ani-
als. However, there was no signiﬁcant difference in TAC levels
etween the malathion-poisoned untreated group and delayed (six
nd 12 h post-exposure) lipid-treatment groups, but TOS levels
ere reduced in all lipid-treated groups. These results were con-
istent with levels of caspase-3. In the chlorpyriphos study, lipid
mulsion was shown to have a protective effect on serum ChE,
t increased TAC and decreased TOS, and when compared with
he chlorpyriphos-only group, apoptosis was reduced in the lipid-
reated groups [101].
Though these studies might show the early use of lipid emul-
ions in OP poisoning as promising, they have limitations: ﬁrst,
LE was not tested together with other antidotes, and second, the
uthors were looking mainly at the antioxidant capacity and apo-
tosis, and not on other clinical aspects of poisoning. As exposure
evels were below the lethal and even the acute clinical toxicity
ange, these results, as well as the oral administration of ILE, may  be
elevant for the low-level, chronic exposure scenarios or long-term
ffects in survivors of acute poisoning.
.5.2. Intraosseous administration
Severely OP-poisoned victims usually suffer from respiratory
nsufﬁciency combined with cardiovascular collapse [116]. Even
hen not in the setting of a mass casualty event, these patients
ose a signiﬁcant challenge to caregivers [121]. We,  and others,
ave previously shown that the intraosseous route is an important
ethod to administer relevant OP antidotes [13,15,41,95,135,136].
ecently, Fettiplace et al. [45] have shown that intraosseous lipid
mulsion can be safely used in emergency situations. This is an
mportant issue when dealing with drug administration during
esuscitation of a poisoned victim. Together with the data we have
n the use of OP antidotes via the intraosseous route, it opens a
otential treatment modality which may  be beneﬁcial in victims of
cute, high-level OP poisoning.
The study of Bania et al. [5] on the effect of ILE in OP poi-
oning was based on intraperitoneal (i.p.) administration. Further
tudies are necessary in order to determine the differences inReports 3 (2016) 202–210
pharmacokinetics and bioavailability of the ILE delivered i.p. versus
the more direct intravenous route.
5.6. The relevance of ILE in the management of OP poisoning
Even though the few reported studies on the role of ILE in OP
poisoning did not show dramatic results concerning the efﬁcacy of
ILE in rescue of poisoned animals, the role of ILE in OP poisoning
refractory to conventional treatment should not be minimized as
evidenced by the report of Mir  and Rasool [90].
Mechanistic considerations discussed below strengthen this
point and justify further research efforts to establish its appropriate
place in the treatment plan.
The mechanisms-of-action of ILE discussed in this manuscript
address more than a single pathophysiological route of nerve agent
or OP pesticide poisoning, as follows:
• “Lipid shuttle”: ILE was shown to extract lipophilic toxicants
from critical organs like the brain and the heart [63]. Under-
standing of the pharmaco/toxicokinetics of the agent in different
exposure modalities is essential in order to identify the opti-
mal  timing of ILE administration. The “lipid shuttle” mechanism
may  be relevant in the case of the CWAs VX and soman due
to their lipophilicity and PK/PD properties. The distribution of
VX is slow, so that lipid trapping (by ILE) may  be efﬁcient in
hampering its accumulation in essential organs like the brain or
heart. The unique property of soman is the rapid “aging” of the
soman-bound ChE that stabilizes the soman-ChE bond making it
refractory to reactivation by oximes [121,122]. Therefore, seques-
tering of unbound soman is important in order to stop it from
further binding to cholinesterase and subsequent ageing.
• Immunomodulatory and anti-inﬂammatory properties: inﬂam-
matory processes in the CNS are pivotal in the pathology of OP
poisoning [9], and in the lung injury that is frequently-associated
with such poisoning [67]. Recently, the -3 polyunsaturated fatty
acid -linolenic acid was shown to be neuroprotective in soman-
poisoned rats [102]. The neuroprotective action of this fatty acid
is pleiotropic in nature and the known anti-inﬂammatory prop-
erties of this and other -3 polyunsaturated fatty acids may  play
part in neuroprotection [110].
• Cardioprotective and hemodynamic properties: these may  be
beneﬁcial in the control of OP-associated pulmonary and cardiac
complications [3,10]. This was  suggested by recently-reported
reversal of severe OP-induced cardiotoxicity in a human patient
by ILE [90].
• Mitochondrial protection, antiapoptotic and antioxidant prop-
erties: poisoning with OP pesticides in humans and with
CWAs in animals are associated with increased oxidative stress
[1,71,92,106,111,140] and with tissue damage, apoptosis and
necrosis of cells in the CNS and in other organs [29,74,87]. Mito-
chondrial dysfunction in the CNS and other tissues, which was
found to occur in OP pesticide poisoning [74] and in nerve-agent
exposure [28], has a causal role in the elicitation of oxidative
imbalance and apoptosis. In vitro studies of the effects of OP
pesticides have shown that their apoptotic effects are mediated
via the mitochondrial signaling pathway and driven by oxidative
rather than cholinergic processes [74]. In the CNS, neuronal apo-
ptosis is a late effect, post-cholinergic, resulting from seizures
[29]. Studies in temporal lobe epilepsy (TLE), a condition that has
many pathological features in common with acute nerve agent
poisoning [29,122], have shown that mitochondrial dysfunction
may  be a causal factor in the generation of seizures [50]. Thus,
the beneﬁcial effects of long-chain fatty acids in mitochondrial
dysfunction [103,112,134] may  have a role in alleviation of toxic
effects in cases of OP poisoning, including seizure control. The
recently published LIPAEMIC article, reported on seven out of 10
ology 
6
i
r
u
l
o
a
O
q
u
a
t
T
p
I
d
I
a
a
b
p
e
l
i
f
i
r
I
o
t
o
c
m
m
r
o
P
c
A
a
s
p
a
r
7
I
s
wA. Eisenkraft, A. Falk / Toxic
bupivacaine-poisoned individuals who developed seizures. These
seizures were terminated by ILE treatment, and only two  of the
patients received an additional anticonvulsant (midazolam) [24].
Although the pathophysiology of seizures in bupivacaine and OP
poisoning may  not be the same, the role of ILE in sequestering the
proconvulsive agents thus preventing exposure of target tissues
warrants further study of their usefulness as anticonvulsants in
OP poisoning as well.
. Potential clinical use and future directions
Sequestration of nerve agents in the blood by scaveng-
ng molecules is an established strategy driving comprehensive
esearch and development efforts [96]. Current bioscavengers
nder development are based on high-afﬁnity binding proteins
ike AChE, BuChE, and praoxonase-1 (PON1) [96]. However, most
f these candidate therapies have not been tested clinically and
re not yet available for use. The ILEs, even though less potent as
P binders than speciﬁc OP targeted agents, are available in large
uantities, have been used clinically for other purposes, and may  be
seful in entrapment of the highly lipophilic nerve agents soman
nd VX, as well as other lipophilic OP compounds, thus affecting
heir toxicity by interference with their distribution to the tissues.
he lipophilic nature of sulfur mustard, together with the latent
eriod from exposure to the development of tissue injury, makes
LE an important potential candidate as a medical countermeasure.
Exposure to OPs, whether intentional or accidental, leads to the
eath of several hundreds of thousand people every year [43,55].
n a mass casualty event involving toxic agents, medical response
ssets should not only be effective, but they should also be readily
vailable and simple to deploy. As is shown in this review, ILE may
e an efﬁcient broad-spectrum antidote, which exerts its antidotal
roperties in a rapid manner. At present, ILE therapy is intended
xclusively for hospital use. However, as it does not impose a heavy
ogistic and operational burden, it is very easy to administer, is eas-
ly packaged and needs no refrigeration, it is very easily adaptable
or prehospital emergency care.
In the hospital setting, no matter how many casualties are
nvolved in an OP poisoning scenario, there might be an important
ole for ILE as an adjunct to currently accepted antidotal treatment.
LE may  be useful in the management of sulfur mustard exposure,
f which the toxic mechanisms are less well-deﬁned and speciﬁc
reatments are still a remote option. As it shares a number of physic-
chemical and toxicodynamic properties with nerve agents, some
ommon treatment modalities for both types of chemical agents
ay  be found [30,31].
In any case, before we can decide on the role of ILE in the treat-
ent of CWA  poisoning, we should direct and conduct a methodical
esearch program aimed at understanding better its mechanism-
f-action in OP and sulfur mustard poisonings, study better its
K/PD, routes and timing of administration, and interactions with
urrently used antidotes in order to design combination therapies.
nother important research direction is the effect of different types
nd compositions of ILE, especially those enriched in -3 polyun-
aturated fatty acids, shown recently to be superior to standard ILE
reparations in the protection of ARDS patients [119,120] and in
nimal models [62], and, as cited above, may  be useful in amelio-
ation of nerve agent neuropathological effects2 [102,110].
. Summary and conclusionsSince many OP compounds and sulfur mustard are li pophilic,
LE might represent a new approach to the treatment of such poi-
onings. In several animal studies with OP pesticides, protection
as not achieved, while other studies like that of Dunn et al. [36]Reports 3 (2016) 202–210 207
showed some changes in the pathophysiology that merits addi-
tional studies. The successful reversal of cardiac arrest following ILE
treatment in a human case of severe parathion poisoning, also sug-
gests ILE may  have a role in the management of severe OP poisoning.
ILE was  not studied so far in the treatment of sulfur mustard injury,
and its potential role in the management of this injury should be
explored. ILE may  help in reducing the time to recovery of patients,
by facilitating the extraction of the poison from the blood and tis-
sues, by adding a large energy supply to the injured tissues, as well
as other agent-dependent pharmacodynamic effects.
An important consideration in establishing a role for ILE in CWA
poisoning is its availability in every hospital, the medical staff is
acquainted with its use, and it is of relatively low cost. All of the
above may warrant it as a simple, available, safe and cheap adjunct
in the medical management of OP and CWA  poisonings.
Transparency document
The http://dx.doi.org/10.1016/j.toxrep.2015.12.007 associated
with this article can be found in the online version.
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